Effects of cell cycle activation on the short-term engraftment properties of ex vivo expanded murine hematopoietic cells

Blood

Volumn 95, Issue 9, 2000, Pages 2829-2837

  Szilvassy, Stephen J ^a,b   Meyerrose, Todd E ^a   Grimes, Barry ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 11; INTERLEUKIN 6; STEM CELL FACTOR; THROMBOPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; GRAFT SURVIVAL; GROWTH STIMULATION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034193069     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.9.2829.009k37_2829_2837     Document Type: Article

References (43)

1. To LB, Roberts MM. Haylock DN. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transpl. 1992;9:277-284.
2. Goldman J. Peripheral blood stem cells for allografting. Blood. 1995;85:1413-1415.
3. Korbling M, Champlin R. Peripheral blood pro-genitor cell transplantation: a replacement for marrow autoor allografts. Stem Cells. 1996;14:185-195.
4. Cairo MS, Wagner JE. Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cells for transplantation. Blood. 1997; 90:4665-4678.
5. Brugger W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med. 1995;333:283-287.
6. + cells in autologous stem cell transplantation for breast cancer. Blood. 1996;67:1687-1691.
7. Holyoake TL, Alcorn MJ, Richmond L, et al. CD34 positive PBSC expanded ex vivo may not provide durable engraftment following myeloablative chemoradiotherapy regimens. Bone Marrow Transpl. 1997;19:1095-1101.
8. Bertolini F, Battaglia M, Pedrazzoli P, et al. Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. Blood. 1997;89:2679-2688.
9. Reiffers J, Cailliot C, Dazey B, Attal M, Caraux J, Boiron JM. Abrogation of post-myeloablative chemotherapy neutropenia by ex vivo expanded autologous CD34-positive cells (letter). Lancet. 1999;354:1092-1093.
10. Srour EF, Abonour R, Cornetta K, Traycoff CM. Ex vivo expansion of hematopoietic stem and progenitor cells: are we there yet? J Hematotherapy. 1999;8:93-102.
11. Muench MO, Firpo MT, Moore MAS. Bone marrow transplantation with interleukin-1 plus kit-ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential. Blood. 1993;81:3463-3473.
12. Szilvassy SJ, WellerKP, Chen B, Juttner CA, Tsukamoto A, Hoffman R. Partially differentiated ex vivo expanded cells accelerate hematologic recovery in myeloablated mice transplanted with highly enriched long-term repopulating stem cells. Blood. 1996;88:3642-3653.
13. Ratajczak MZ, Ratajczak J. Machalinski B, Mick R, Gewirtz AM. In vitro and in vivo evidence that ex vivo cytokine priming of donor marrow cells may ameliorate posttransplant thrombocytopenia. Blood. 1998;92:353-359.
14. Albella B, Segovia JC, Bueren JA. Does the granulocyte-macrophage colony-forming unit content in ex vivo-expanded grafts predict the recovery of the recipient leukocytes? Blood. 1997;90:464-470.
15. Szilvassy SJ, Bass MJ, Van Zant G, Grimes G. Organ-selective homing defines the engraftment kinetics of murine hematopoietic stem cells and is compromised by ex vivo expansion. Blood. 1999; 93:1557-1566.
16. van der Loo JCM, Ploemacher RE. Marrow-and spleen-seeding efficiencies of all murine hematopoietic stem cell subsets are decreased by preincubation with hematopoietic growth factors. Blood. 1995;85:2598-2606.
17. Monette FC, DeMello JB. The relationship between stem cell seeding efficiency and position in cell cycle. Cell Tissue Kinet. 1979;12:161-175.
18. + cells in non-obese diabetic/severe combined immune-deficient mice. Blood. 1998;92:2641-2649.
19. Habibian HK, Peters SO, Hsieh CC, et al. The fluctuating phenotype of the lymphohematopoietic stem cell with cell cycle transit. J Exp Med. 1998;188:393-398.
20. Guigon M, Mary JY, Enout J, Frindel M. Protection of mice against lethal doses of 1-β-D-arabinofuranosylcytosine by pluripotent stem cell inhibitors. Cancer Res. 1982;42:638-641.
21. Carde P, Chastang C, Goncalves E, et al. Seraspenide (acetylSDKP): phase I-II trial study of inhibitor of hematopoiesis protects against toxicity of aracytine and ifosfamise monochemotherapies. C R Acad Sci III. 1992;315:545-550.
22. Suzuki A, Aizawa S, Araki S, et al. Enhanced engraftment of intravenously transplanted hematopoietic stem cells into bone marrow of irradiated mice treated with AcSDKP. Exp Hematol. 1998; 26:79-83.
23. Fleming WH, Alpern EJ, Uchida N, Ikuta K, Spangrude GJ, Weissman IL. Functional heterogeneity is associated with the cell cycle status of murine hematopoietic stem cells. J Cell Biol. 1993;122: 897-902.
24. Cashman JD, Eaves AC, Eaves CJ. The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long-term culture: evidence for an indirect mechanism. Blood. 1994;84:1534-1542.
25. Jackson JD, Van Y, Ewel C, Talmadge JE. Activity of Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) on hematopoietic progenitor cells in short-term and long-term murine bone marrow cultures. Exp Hematol. 1996;24:475-481.
26. Petzer AL, Hogge DE, Lansdorp PM, Reid DS, Eaves CJ. Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Sci U S A. 1996;93:1470-1474.
27. Piacibello W, Sanavio F, Garetto L, et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood. 1997;89:2644-2653.
28. Bhatia M, Bonnet D, Kapp U, Wang JCY, Murdoch B, Dick JE. Quantitative analysis reveals expansion of human hematopoietic repopulating cells after short-term ex vivo culture. J Exp Med. 1997;186:619-624.
29. Conneally E, Cashman J, Petzer A, Eaves C. Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice. Proc Natl Acad Sci U S A. 1997;94:9836-9841.
30. 1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood. Blood. 1997;89: 465-472.
31. Wiesmann A, Kim MJ, Georgelas A, et al. Modulation of hematopoietic stem/progenitor cell engraftment by transforming growth factor-β. Exp Hematol. 2000; in press.
32. - cells: possible explanation for differences in post-transplant engraftment kinetics? [abstract] Exp Hematol. 1999;27(suppl 1): 127.
33. 2/M phases of the cell cycle. Blood. 1998;92: 842-848.
34. + Lin cells fractionated on the basis of adhesion molecule expression and cell cycle position [abstract]. Blood. 1998;92[suppl 1]:584a.
35. Becker PS, Nilsson SK, Li Z, et al. Adhesion receptor expression by hematopoietic cell lines and murine progenitors: modulation by cytokines and cell cycle status. Exp Hematol. 1999;27:533-541.
36. Williams DA, Rios M, Stephens C, Patel VP. Fibronectin and VLA-4 in haematopoietic stem cell-microenvironment interactions. Nature. 1991;352: 438-441.
37. Papayannopoulou T, Craddock C, Nakamoto B, Priestley GV, Wolf NS. The VLA-4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgment of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci U S A. 1995;92:9647-9651.
38. Zanjani ED, Flake AW, Almeida-Porada G, Tran N, Papayannopoulou T. Homing of human cells in the fetal sheep model: modulation by antibodies activating or inhibiting very late activation antigens-dependent function. Blood. 1999;94:2515-2522.
39. Traycoft CM, Yoder MC, Hiatt K, Srour EF. Functional association between expression of adhesion molecules and marrow repopulating potential of primitive murine hematopoietic progenitor cells (HPC) [abstract]. Exp Hematol. 1997;25: 736.
40. + cells in grafts and time to myeloid and platelet recovery after autologous stem cell transplantation. Exp Hematol. 1998;26:10-18.
41. Lenfant M, Itoh K, Sakoda H, et al. Enhancement of the adherence of hematopoietic stem cells to mouse bone marrow-derived stromal cell line MS-1-T by a tetrapeptide acetyl-N-Ser-Asp-Lys-Pro. Exp Hematol. 1989;17:898-902.
42. Bonnet D, Lemoine FM, Khoury E, Pradelles P, Najman A, Guigon M. Reversible inhibitory effects and absence of toxicity of the tetrapepticte Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) in human long-term bone marrow culture. Exp Hematol. 1992; 20:1165-1169.
43. Eaves CJ, Cashman JD, Wolpe SD, Eaves AC. Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein-1α, an inhibitor of primitive normal hematopoietic cells. Proc Natl Acad Sci U S A. 1993;90: 12,015-12,019.